Paul Tudor Jones sees potential market rally after late October
Quantum-Si Inc (NASDAQ:QSI), a volatile biotech company with a market capitalization of $327 million, reported that Chief Financial Officer Jeffry R. Keyes sold 7,746 shares of Class A Common Stock on September 22 and 23, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The total value of the shares sold was $12,849.
On September 22, Keyes sold 3,873 shares at a weighted average price of $1.6826, with prices ranging from $1.64 to $1.72. On September 23, he sold another 3,873 shares at a weighted average price of $1.635, with prices ranging from $1.57 to $1.79. The stock, which has shown significant volatility with a beta of 2.87, has recently demonstrated strong momentum with a 28% return over the past week.
The sales were executed to cover required federal, state, and local withholding taxes associated with the vesting of previously granted restricted stock units, according to the filing. Following the transactions, Keyes directly owns 1,171,824 shares of Quantum-Si Inc. According to InvestingPro, the company maintains strong liquidity with a current ratio of 9.43, and investors can access 8 additional exclusive insights about QSI’s financial health and market position through the Pro Research Report.
In other recent news, Quantum-Si Incorporated reported its financial results for the second quarter of 2025. The company posted an earnings per share (EPS) of -$0.16, slightly missing the analysts’ forecast of -$0.14. Despite the EPS miss, Quantum-Si achieved a revenue surprise of 15.7% over expectations, with actual revenue reaching $591,000. However, this revenue figure still fell short of some estimates. In addition to its earnings report, Quantum-Si announced the release of its V4 Sequencing Kit. This new kit is compatible with both Platinum and Platinum Pro instruments and enhances protein analysis capabilities. The kit offers improved sequencing coverage through the addition of glycine recognition, enhanced alanine and serine recognition, and an enzyme designed to cut through amino acids directly preceding proline. These developments are part of the company’s ongoing efforts to advance its technological offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.